Clinical Trial Update: Oblimersen in Treating Patients With Merkel Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating oblimersen (Genasense) for Merkel cell carcinoma (neuroendocrine carcinoma of the skin) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Genasense (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin | Phase 2 | Status: COMPLETED